clinical trial · NCT07229729
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase2·recruiting·n = 300
Non-small Cell Lung CancerSHR-A2102AdebrelimabPaclitaxelCarboplatinAlomnertinib MesilateFurmonertini MesilateOsimertinib Mesylate
brief summary
The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
started
Nov 24, 2025
primary completion
Oct 1, 2026
completion
Oct 1, 2029
last updated
Dec 1, 2025
official title
A Randomized, Open-label, Multicenter Phase II Clinical Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol